v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company has one operating segment. The Company's operating segment discovers and develops therapies for CNS disorders. The Company's chief operating decision maker ("CODM"), its Chief Executive Officer, manages the Company's operations on a consolidated basis for the purposes of assessing performance and allocating resources based on net loss that also is reported on the condensed consolidated statement of operations as consolidated net loss. Net loss is used by the CODM to make key strategic and operational decisions. The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets. The majority of the Company's long-lived assets are held in the United States.
The following table presents selected financial information about the Company's single operating segment for the three and six months ended June 30, 2026 and 2025 (in thousands):
Three Months Ended
June 30,		Six Months Ended June 30,
2026202520262025
Program-specific expenses:
Ulixacaltamide$13,299 $18,385 $32,402 $41,898 
Vormatrigine12,878 17,957 33,372 31,690 
Relutrigine13,979 10,509 26,833 15,886 
Elsunersen8,141 1,317 11,338 2,078 
Other early stage assets5,471 1,417 8,713 2,522 
Personnel-related expenses18,943 11,913 36,673 24,943 
Stock-based compensation expense11,309 7,770 28,421 16,556 
Depreciation expense33 46 72 93 
Other segment expenses(a)
12,851 6,753 24,940 15,129 
Other income, net13,184 4,940 26,483 10,372 
Consolidated net loss$(83,720)$(71,127)$(176,281)$(140,423)
(a) Other segment expenses includes research and development and general and administrative costs not attributable to a specific program.